We are part of the CSL Limited group of companies. See how we're Driven by Our Promise.
We collaborate with rare disease organizations to promote quality medical care and services.
We offer a variety of support programs and activities for the patients we serve.
We also aim to make sure that nothing holds you back from getting the therapies you need.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise.
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health.
We work every day as if someone’s life depends on it, because it does.
We manufacture products to treat a number of rare diseases.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL Behring.
Mom-to-be Danielle D. on overcoming her rare disease to live the life she has always envisioned.
In a Q&A with RARE Revolution magazine, CSL Behring’s Camilla Shen explains why demand is high: More patients are getting dia…
Primary immunodeficiencies are complex problems with the immune system that make people more vulnerable to serious infections…
Learn how to join with the global community to raise awareness about primary immunodeficiency diseases.
Outnumbered by people with healthy immune systems, patients share COVID-19 pandemic perspectives in reports in The Philadelph…
Colds are circulating and it’s flu season. Time to test your knowledge about keeping hands clean.
Even prior to the Omicron variant, U.S. experts urged four COVID-19 shots for this group after research found the vaccines pr…
In an update, immunologist says most PID patients appear no more at risk than the general population.
A new video campaign asks real patients from around the world to look in the camera and explain why plasma donations matter.
U.S. agencies recommend a third COVID-19 vaccine for primary immunodeficiency patients and organ transplant recipients.
Different than an IV, this method delivers medicine below the skin and can be self-administered by some patients.
CSL brought together 300 researchers and clinicians from more than 30 countries for a virtual conference.
Popular search terms:
Americas
Asia Pacific
Middle East
Europe
